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do the Editor: There are questions regarding long-term safety of
rug-eluting stents (DES), especially concern about an in-
reased rate of late DES thrombosis compared with bare-metal
tents. Numerous intravascular ultrasound (IVUS) studies have
eported an increased frequency of late stent malapposition
LSM) in patients with DES (1–3), speculating that there may
e a relationship between LSM and late stent thrombosis. The
resent study reports the long-term (2 years) follow-up after
he diagnosis of LSM was made using serial IVUS examination
fter DES implantation.
We previously reported 82 patients (85 lesions) with LSM from
n overall cohort of 557 patients (705 native lesions) who under-
ent DES implantation (mean interval between baseline and
ollow-up IVUS of 6.1  2.1 months). No intervention was
erformed in 542 patients (683 lesions) at 6-month follow-up (3).
t least 2-year follow-up was available for all but 10 patients (12
esions). Therefore, the present study reports 532 patients (98%
ollow-up rate) with 671 lesions; 80 patients (83 lesions) had LSM,
nd 452 patients (588 lesions) did not.
Long-term (i.e., beyond 6 months) clinical follow-up data were
btained from outpatient records or telephone interviews. Major
dverse cardiac events (MACE) were defined as cardiac death,
cute myocardial infarction (AMI), or target lesion revasculariza-
ion (TLR). Death, AMI, TLR, and stent thrombosis were
efined according to Academic Research Consortium criteria (4).
ll patients were followed for a minimum of 24.0 months (range
4.0 to 41.6 months) after the 6-month follow-up angiogram and
VUS, except for the patients who were lost to follow-up or who
ad MACE events during the 2-year follow-up period.
Serial IVUS imaging and analysis were performed as previously
escribed (3). Late stent malapposition was defined as a separation
f at least 1 stent strut from the intimal surface of the arterial wall
hat was not present immediately after stent implantation.
Data were compared with chi-square statistics or Fisher exact
est and unpaired Student t test or Mann-Whitney U test.
vent-free survival was analyzed with the Kaplan-Meier method
nd log-rank test. Multiple stepwise logistic regression analysis was
erformed to assess independent predictors for MACE.
Late stent malapposition (mean area of 3.0 mm2) was docu-
ented in 80 patients with 83 lesions (12.4%). The duration of
linical follow-up was 31  6 months after the 6-month angio-
ram: 32  6 months in LSM patients and 31  6 months in
on-LSM patients (p  0.3). The duration of follow-up after
essation of dual antiplatelet therapy was 27 9 months and 27
months, respectively (p  1.0).
There was 1 cardiac death (1.3%) and 1 AMI (1.3%) in theSM group, whereas in the non-LSM group there were 2 cardiac meaths (0.4%) and 2 AMIs (0.4%) (p  0.2). The cause of all 3
MIs was very late definite stent thrombosis 21, 24, and 27
onths after the 6-month angiogram and 18 to 24 months after
topping clopidogrel (Table 1). Target lesion revascularization was
ecessary in 1 LSM patient (1.3%) and in 8 non-LSM patients
1.8%; p  0.7). Clinical profiles of the 15 patients who developed
ACE events during follow-up are shown in Table 1. There was
o significant difference in 3-year MACE-free survival rate be-
ween the 2 groups (log rank p  0.7). Postprocedural incomplete
tent apposition, which was observed in 51 lesions, was not related
ith any MACE for the 3-year follow-up.
Multiple stepwise logistic regression analysis was performed to
etermine predictors of MACE. The following variables were
ested (all variables with p  0.2 in univariate analysis): age,
reintervention minimal lumen diameter, and total stent length.
ate stent malapposition and LSM area were forced into the
odel. There were no significant independent predictors for
ACE.
Numerous studies have speculated that LSM is a cause of late
tent thrombosis after DES implantation. A recent study reported
hat incomplete stent apposition was related to very late stent
hrombosis. However, lack of post-stent IVUS was a significant
imitation (5). Our study and other studies have reported no
egative clinical events associated with LSM treated with DES
mplantation (1–3). Degertekin et al. (6) reported 13 patients from
he RAVEL (Randomized Comparison of a Sirolimus-Eluting
tent With a Standard Stent for Coronary Revascularization)
tudy, who received sirolimus-eluting stents, showed stent malap-
osition at angiographic follow-up, and remained asymptomatic
uring the subsequent 12-month period. However: 1) these
revious studies were multicenter randomized studies with specific
ndications excluding complex lesions; 2) with the exception of the
AXUS-II (Paclitaxel-Eluting Stents in the Treatment of Longer
esions) study, the number of patients in each IVUS substudy was
mall, often representing 25% of the DES cohort; 3) added
ogether, these IVUS substudies did not include the number of
SM patients in the present report; 4) the size of the stent-vessel
all gaps were modest; and 5) follow-up was limited to 12 months
eyond the 6- or 9-month angiogram and IVUS, similar to our
revious report (3). The present analysis was designed to overcome
ome of these previous limitations, especially the duration of
ollow-up. The mean follow-up beyond the 6-month angiogram
nd IVUS in the current report was 31 months, 27 months without
ual antiplatelet therapy, and thus was much longer than these
ulticenter studies.
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October 9, 2007:1515–21This was a retrospective observational analysis without addi-
ional angiographic or IVUS data (IVUS study at the time of
ate stent thrombosis or longitudinal IVUS). This study is
nderpowered to show a significant difference in MACE rates
etween LSM versus non-LSM patients during a mean 31
onths of clinical follow-up after the 6-month angiogram. The
elationship between LSM, LSM area, or duration of antiplate-
et treatment and MACE requires further analysis with a larger
umber of patients.
In conclusion: 1) MACE and stent thrombosis were not more
requent in LSM patients compared with non-LSM patients; and
) LSM after DES implantation was not a predictor of MACE
uring a mean follow-up of 31 months after the 6-month IVUS in
cohort of this size.
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linical Profiles of the 15 Patients Who Developed MACE During Follow-Up
Table 1 Clinical Profiles of the 15 Patients Who Developed MACE Durin
Patient #
Age
(yrs) Gender
Clinical/
Angiographic
Diagnosis
Risk
Factors Site
LS
LSM patients
1 61 F UAP/2VD D, H LCX
2 40 M AMI/1VD D, H, S LAD
3 33 M UAP/2VD S LAD
Non-LSM patients
4 48 M AMI/2VD S LCX
5 66 M UAP/2VD H LAD
6 54 M AMI/2VD H LAD
7 60 M SAP/3VD RCA
8 50 M UAP/1VD H LAD
9 38 M UAP/1VD D, H, S, C LAD
10 63 F SAP/3VD D LAD
11 66 M SAP/3VD S LAD
12 58 F SAP/3VD RCA
13 63 F UAP/2VD H RCA
14 67 M SAP/3VD C LAD
15 52 M SAP/2VD D, H LAD
MI  acute myocardial infarction; C  hypercholesterolemia; CSA  cross-sectional area; D  di
left circumflex artery; LSM  late stent malapposition; MACE  major adverse cardiac events;
AP  stable angina pectoris; SES  sirolimus-eluting stent; TLR  target lesion revascularizatioDepartment of Medicine
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ongpa-gu, Seoul, 138-736
orea
-mail: sjpark@amc.seoul.kr
doi:10.1016/j.jacc.2007.07.038
EFERENCES
. Tanabe K, Serruys PW, Degertekin M, et al. Incomplete stent apposition
after implantation of paclitaxel-eluting stents or bare metal stents: insights
from the randomized TAXUS II trial. Circulation 2005;111:900–5.
. Ako J, Morino Y, Honda Y, et al. Late incomplete stent apposition after
sirolimus-eluting stent implantation: a serial intravascular ultrasound
analysis. J Am Coll Cardiol 2005;46:1002–5.
. Hong MK, Mintz GS, Lee CW, et al. Late stent malapposition after
drug-eluting stent implantation; an intravascular ultrasound analysis
with long-term follow-up. Circulation 2006;113:414–9.
. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in
coronary stent trials; a case for standardized definitions. Circulation
2007;115:2344–51.
. Cook S, Wenaweser P, Togno M, et al. Incomplete stent apposition
and very late stent thrombosis after drug-eluting stent implantation.
Circulation 2007;115:2426–34.
. Degertekin M, Serruys PW, Tanabe K, et al. Long-term follow-up of
incomplete stent apposition in patients who received sirolimus-eluting
stent for de novo coronary lesions: an intravascular ultrasound analysis.
Circulation 2003;108:2747–50.
ow-Up
A/MSA
2)
Type, Number
(Length, mm)
of DES
Clopidogrel
Treatment
(Months) After
6-Month
Angiogram
MACE and Their Onset
After 6-Month
Angiogram
6.6 SES, 1 (18) 2 Death, 25 months
3.4 SES, 3 (18,33,33) 3 AMI, 21 months
8.9 SES, 2 (33/33) 0 TLR, 16 months
6.2 SES, 1 (23) 3 AMI, 27 months
9.3 SES, 2 (23,23) 5 Death, 31 months
5.1 PES, 1 (24) 2 AMI, 24 months
9.8 SES, 1 (33) 2.6 Death, 2.6 months
6.3 SES, 2 (18,23) 4 TLR, 14 months
6.5 PES, 2 (24,28) 8 TLR, 8 months
4.8 SES, 1 (33) 11 TLR, 20 months
9.4 SES, 1 (28) 2 TLR, 25 months
6.8 SES, 2 (23,23) 0 TLR, 20 months
5.2 SES, 1 (23) 8 TLR, 8 months
6.1 SES, 2 (23,33) 13 TLR, 15 months
3.0 SES, 3 (18,33,33) 0 TLR, 13 months
mellitus; DES  drug-eluting stent; H  hypertension; LAD  left anterior descending artery; LCX
minimum stent area; PES  paclitaxel-eluting stent; RCA  right coronary artery; S  smoking;
 unstable angina pectoris; VD  vessel disease.g Foll
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